Compare RILYP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RILYP | VCEL |
|---|---|---|
| Founded | 1973 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.1B |
| IPO Year | 2014 | 1996 |
| Metric | RILYP | VCEL |
|---|---|---|
| Price | $7.73 | $39.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $59.71 |
| AVG Volume (30 Days) | 10.9K | ★ 511.9K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | ★ 138.49 | 60.00 |
| EPS | ★ 6.47 | N/A |
| Revenue | ★ $967,599,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $21.71 |
| Revenue Next Year | N/A | $16.86 |
| P/E Ratio | $1.20 | ★ N/A |
| Revenue Growth | 15.38 | ★ 16.45 |
| 52 Week Low | $3.25 | $28.95 |
| 52 Week High | $17.52 | $49.32 |
| Indicator | RILYP | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 17.39 | 48.55 |
| Support Level | N/A | $37.78 |
| Resistance Level | $13.63 | $41.21 |
| Average True Range (ATR) | 0.53 | 1.29 |
| MACD | -0.16 | 0.13 |
| Stochastic Oscillator | 9.12 | 47.50 |
BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services, telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across various business lines. The Group has seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Capital Markets segment, which provides investment banking and institutional brokerage services, offers loans, trades in equity securities, and maintains an investment portfolio of public and private equities and debt securities. Geographically, the Group derives maximum revenue from its business in North America.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.